# EDGAR Filing Document

**Accession Number:** 0001610618
**File Stem:** 0001610618-25-000082
**Filing Date:** 2025-8
**Character Count:** 21633
**Document Hash:** ef1ed256438e668a45673c931089f46d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001610618-25-000082.hdr.sgml**: 20250807

**ACCESSION NUMBER**: 0001610618-25-000082

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**REFERENCES 429**: 333-281523

**FILED AS OF DATE**: 20250807

**DATE AS OF CHANGE**: 20250807

**EFFECTIVENESS DATE**: 20250807

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cidara Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001610618
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 461537286
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289363
- **FILM NUMBER:** 251194464

**BUSINESS ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-752-6170

**MAIL ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** K2 THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20140611

**As filed with the Securities and Exchange Commission on August 7, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**CIDARA THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **46-1537286** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| **6310 Nancy Ridge Drive, Suite 101**<br>**San Diego, California** | **92121** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**Cidara Therapeutics, Inc. 2024 Equity Incentive Plan, as amended**

(Full titles of the plans)

Jeffrey Stein, Ph.D.

President and Chief Executive Officer

Cidara Therapeutics, Inc.

6310 Nancy Ridge Drive, Suite 101

San Diego, California 92121

(858) 752-6170

(Name, address, including zip code, and telephone number, including area code, of agent for service)

*Copies to:* 

---

| | |
|:---|:---|
| Charles J. Bair, Esq.<br>Cooley LLP<br>10265 Science Center Drive<br>San Diego, California 92121<br>(858) 550-6000 | Jeffrey Stein, Ph.D.<br>President and Chief Executive Officer<br>Cidara Therapeutics, Inc.<br>6310 Nancy Ridge Drive, Suite 101<br>San Diego, California 92121 |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | □ | Accelerated filer | □ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧ |
| | | Emerging growth company | □ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. □

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed by Cidara Therapeutics, Inc. (the "***Registrant***") for the purpose of registering an additional 2,880,000 shares of the Registrant's common stock, par value $0.0001 per share (the "***Common Stock***"), under the Registrant's 2024 Equity Incentive Plan, as amended (the "***2024 EIP***"), pursuant to an amendment to the 2024 EIP approved by the Board of Directors of the Registrant on March 14, 2025, subject to stockholder approval, which was obtained at the Registrant's Annual Meeting of Stockholders held on June 18, 2025.

**INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION**

**STATEMENT ON FORM S-8**

This Registration Statement on Form S-8 is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same benefit plan is effective.

The Registrant previously registered shares of its Common Stock for issuance under the 2024 EIP under a Registration Statement on Form S-8 filed with the Securities and Exchange Commission on <u>[August 13, 2024](https://www.sec.gov/Archives/edgar/data/1610618/000161061824000119/cdtxs-82024x08x13.htm)</u> (File No. 333-281523).

Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statement referenced above.

**ITEM 8. EXHIBITS.**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 4.1 | <u>[Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on April 24, 2015).](https://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex31.htm)</u> |
| 4.2 | <u>[Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant's Annual Report on Form 10-K, filed with the SEC on April 22, 2024).](https://www.sec.gov/Archives/edgar/data/1610618/000161061824000041/exhibit322023-12.htm)</u> |
| 4.3 | <u>[Certificate of Amendment to Amended and Restated Certificate of Incorporation of Cidara Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on July 18, 2024).](https://www.sec.gov/Archives/edgar/data/1610618/000161061824000091/exhibit312024-07x18.htm)</u> |
| 4.4 | <u>[Certificate of Amendment to Amended and Restated Certificate of Incorporation of Cidara Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on June 20, 2025).](https://www.sec.gov/Archives/edgar/data/1610618/000161061825000072/exhibit312025-06x20.htm)</u> |
| 4.5 | <u>[Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K, filed on April 24, 2015).](https://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex32.htm)</u> |
| 4.6 | <u>[Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on May 21, 2018).](https://www.sec.gov/Archives/edgar/data/1610618/000161061818000052/ex312018-05x21.htm)</u> |
| 4.7 | <u>[Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Voting Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on April 24, 2024).](https://www.sec.gov/Archives/edgar/data/1610618/000161061824000051/exhibit312024-04x24.htm)</u> |
| 4.8 | <u>[Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed on March 13, 2015).](https://www.sec.gov/Archives/edgar/data/1610618/000119312515119340/d843130dex41.htm)</u> |
| 5.1\* | <u>[Opinion of Cooley LLP.](exhibit512025-08x07.htm)</u> |
| 23.1\* | <u>[Consent of Independent Registered Public Accounting Firm.](exhibit2312025-08x07.htm)</u> |
| 23.2\* | <u>[Consent of Cooley LLP. Reference is made to Exhibit 5.1.](exhibit512025-08x07.htm)</u> |
| 24.1\* | <u>[Power of Attorney. Reference is made to the signature page hereto.](#i52bcd8a96b9b49549aec7af44bfa69cc_4)</u> |
| 99.1 | <u>[Cidara Therapeutics, Inc. 2024 Equity Incentive Plan, as amended, Form of Grant Notice, Stock Option Agreement and Notice of Exercise, and Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement thereunder](https://www.sec.gov/Archives/edgar/data/1610618/000161061825000072/exhibit1012025-06x20.htm)[(incorporated by reference to Exhibit](https://www.sec.gov/Archives/edgar/data/1610618/000161061825000072/exhibit1012025-06x20.htm)[10](https://www.sec.gov/Archives/edgar/data/1610618/000161061825000072/exhibit1012025-06x20.htm)[.1 to the Registrant's Current Report on Form 8-K, filed on June 20, 2025).](https://www.sec.gov/Archives/edgar/data/1610618/000161061825000072/exhibit1012025-06x20.htm)</u> |
| 107\* | <u>[Filing Fee Table.](exfilingfees.htm)</u> |

---

\* Filed herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on August 7, 2025.

---

| | |
|:---|:---|
| **CIDARA THERAPEUTICS, INC.** | **CIDARA THERAPEUTICS, INC.** |
| By: | /s/ Jeffrey Stein, Ph.D. |
|  | Jeffrey Stein, Ph.D. |
|  | *President and Chief Executive Officer* |

---

**POWER OF ATTORNEY** 

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jeffrey Stein, Ph.D. and Frank Karbe and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Jeffrey Stein, Ph.D. | President, Chief Executive Officer and<br>Member of the Board of Directors<br>*(Principal Executive Officer)* | August 7, 2025 |
| **Jeffrey Stein, Ph.D.** | President, Chief Executive Officer and<br>Member of the Board of Directors<br>*(Principal Executive Officer)* |  |
| /s/ Frank Karbe | Chief Financial Officer<br>*(Principal Financial Officer and*<br>*Principal Accounting Officer)* | August 7, 2025 |
| **Frank Karbe** | Chief Financial Officer<br>*(Principal Financial Officer and*<br>*Principal Accounting Officer)* |  |
| /s/ Daniel D. Burgess | Chairman of the Board of Directors | August 7, 2025 |
| **Daniel D. Burgess** |  |  |
| /s/ Bonnie Bassler, Ph.D. | Member of the Board of Directors | August 7, 2025 |
| **Bonnie Bassler, Ph.D.** |  |  |
| /s/ Carin Canale-Theakston | Member of the Board of Directors | August 7, 2025 |
| **Carin Canale-Theakston** |  |  |
| /s/ James Merson, Ph.D. | Member of the Board of Directors | August 7, 2025 |
| **James Merson, Ph.D.** |  |  |
| /s/ Chrysa Mineo | Member of the Board of Directors | August 7, 2025 |
| **Chrysa Mineo** |  |  |
| /s/ Josh Resnick, M.D. | Member of the Board of Directors | August 7, 2025 |
| **Josh Resnick, M.D.** |  |  |
| /s/ Theodore R. Schroeder | Member of the Board of Directors | August 7, 2025 |
| **Theodore R. Schroeder** |  |  |
| /s/ Ryan Spencer | Member of the Board of Directors | August 7, 2025 |
| **Ryan Spencer** |  |  |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Cidara Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Cidara Therapeutics, Inc. 2024 Equity Incentive Plan, as amended (Common Stock, $0.0001 par value per share) | Other | 2880000 | $61.243 | $176379840.00 | 0.0001531 | $27003.75 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $176379840.00  |  | $27003.75  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $27003.75  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock, par value $0.0001 per share ("Common Stock"), of Cidara Therapeutics, Inc. (the "Registrant") that become issuable under the Cidara Therapeutics, Inc. 2024 Equity Incentive Plan, as amended (the "2024 EIP") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of Common Stock. This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The price per share and aggregate offering price are based upon the average of the high and low prices of the Common Stock on August 5, 2025, as reported on the Nasdaq Capital Market. Represents an increase in the number of shares of Common Stock reserved for issuance under the 2024 EIP pursuant to an amendment to the 2024 EIP approved by the Board of Directors of the Registrant on March 14, 2025, subject to stockholder approval, which was obtained at the Registrant's Annual Meeting of Stockholders held on June 18, 2025.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---

## Exhibit 5.1

---

| | |
|:---|:---|
| ![cooleylogoa05.jpg](cooleylogoa05.jpg) | **Exhibit 5.1** |

---

Charles J. Bair

+1 858 550 6142

cbair@cooley.com

August 7, 2025

Cidara Therapeutics, Inc.

6310 Nancy Ridge Drive, Suite 101

San Diego, California 92121

**Re: Registration Statement on Form S-8**

Ladies and Gentlemen:

We have acted as counsel to Cidara Therapeutics, Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering of up to 2,880,000 shares (the "***Shares***") of the Company's common stock, $0.0001 par value per share, issuable pursuant to the Company's 2024 Equity Incentive Plan, as amended (the "***Plan***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement, (b) the related prospectus, (c) the Plan, (d) the Company's certificate of incorporation and bylaws, each as currently in effect, and (e) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than by the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement and the prospectus, will be validly issued, fully paid and nonassessable (except as to Shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

Cooley LLP 10265 Science Center Drive San Diego, CA 92121

t: (858) 550-6000 f: (858) 550-6420 cooley.com

------

![cooleylogoa05.jpg](cooleylogoa05.jpg)

August 7, 2025

Page Two

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

Cooley LLP

By: <u>/s/ Charles J. Bair</u>

Charles J. Bair

Cooley LLP 10265 Science Center Drive San Diego, CA 92121

t: (858) 550-6000 f: (858) 550-6420 cooley.com

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2024 Equity Incentive Plan, as amended, of Cidara Therapeutics, Inc. of our report dated March 6, 2025, with respect to the consolidated financial statements of Cidara Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Diego, California

August 7, 2025

<br>